News
A promising new drug may finally bring hope to people suffering from a common but often overlooked cause of high blood ...
AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary endpoints in the BaxHTN Phase III trial, effectively lowering blood pressure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results